

Review

Open Access



# A review on Parkinson's disease treatment

Tori K. Lee, Eva L. Yankee

Department of Biology, Pacific Union College, Angwin, CA 94508, USA.

**Correspondence to:** Tori K. Lee, Department of Biology, Pacific Union College, 1 Angwin Ave, Angwin, CA 94508, USA.  
E-mail: tolee@puc.edu

**How to cite this article:** Lee TK, Yankee EL. A review on Parkinson's disease treatment. *Neuroimmunol Neuroinflammation* 2021;8:222-44. <http://dx.doi.org/10.20517/2347-8659.2020.58>

**Received:** 1 Oct 2020 **First Decision:** 1 Dec 2020 **Revised:** 15 Dec 2020 **Accepted:** 24 Dec 2020 **Available online:** 2#6WU2021

**Academic Editors:** Athanassios P. Kyritsis, Backil Sung **Copy Editor:** Monica Wang **Production Editor:** Jing Yu

## Abstract

Parkinson's disease (PD) is a neurodegenerative illness and has a common onset between the ages of 55 and 65 years. There is progressive development of both motor and non-motor symptoms, greatly affecting one's overall quality of life. While there is no cure, various treatments have been developed to help manage the symptoms of PD. Management of PD is a growing field and targets new treatment methods, as well as improvements to old ones. Pharmacological, surgical, and therapeutic treatments have allowed physicians to treat not only the main motor symptoms of PD, but target patient-specific problems as they arise. This review discusses both the established and new possibilities for PD treatment that can provide patient-specific care and mitigate side effects for common treatments.

**Keywords:** Parkinson's disease, Parkinson's treatment, substantia nigra, basal ganglia, Lewy bodies,  $\alpha$ -synuclein, dopamine, levodopa

## INTRODUCTION

### Basics of Parkinson's disease

Parkinson's disease (PD), or paralysis agitans, is a common neurodegenerative condition, which typically develops between the ages of 55 and 65 years<sup>[1]</sup>. This disease was first named and described by James Parkinson in 1817. The progression of this disease is gradual and prolonged. It has a plausible familial incidence, although the estimates of these occurrences are low and usually sporadic<sup>[2]</sup>. This disease is organized into two classifications: genetic and sporadic. Genetic PD follows Mendelian inheritance.



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



Sporadic PD, which accounts for about 90% of all Parkinson's cases, is a more complex category in which the pathogenic mechanisms that underlie it are not yet fully understood<sup>[3]</sup>. Nonetheless, it is known that the byzantine interactions of genetic and environmental influences play roles in the determination of sporadic PD<sup>[3-5]</sup>. Several subtypes of PD exist. Each has its own set of causative factors and susceptibilities, pathology, and treatment courses. General risk factors, symptoms, and pathology will be discussed first, before addressing some of the subtypes.

### General risk factors

Research studies have linked theories regarding the outbreak of PD to both environmental and genetic circumstances<sup>[6]</sup>. These theories propose associations between PD and chemical reactions, neurotoxins, and genetic susceptibility or predisposition<sup>[3,7-9]</sup>. Environmental determinants positively associated with PD include factors such as injuries to the head, rural living, pesticides, anxiety and/or depression, and intake of dairy products; whereas physical inactivity, smoking, consumption of coffee and/or alcohol, and serum uric acid concentration are reported as having an inverse relationship to PD<sup>[5]</sup>. Though it is undisputed that familial factors play a role in this disease, the extent of heritability is heavily debated. As of yet, 41 different genetic loci have been linked to PD pathogenesis through the completion of 6 large meta-analysis studies<sup>[3]</sup>.

### General symptoms

A precedent for the clinical diagnosis of PD, according to the Movement Disorder Society, is centralized on a motor syndrome, Parkinsonism, and is based on three overriding motor symptoms (MS): bradykinesia, rigidity, and resting tremor<sup>[2]</sup>. Onset of motor manifestations usually begins unilaterally with asymmetrical effects enduring on the side of commencement<sup>[1]</sup>.

Symptoms include resting tremor, bradykinesia, gait, speech difficulties, hypophonia, muscle dystrophy, postural deformities and instability<sup>[10]</sup>. Pain, stiffness or numbness in limbs, bradykinesia, tremors, a decline in facial expressions, and hypophonia are motor symptoms seen in the early stages of this disease's onset<sup>[1,10]</sup>. Late-stage motor features may include motor fluctuations, dyskinesia, gait freezing, and falling. Initial diagnosis may be made based on evaluation of clinical features of patient history and examination<sup>[11]</sup>. Positive or negative responses to dopamine agents may also be used in the diagnosis of PD over time<sup>[1]</sup>.

Since motor symptoms are the traditional primary identifiers of PD, common non-motor symptoms have been under-reported, often being overlooked or untreated. While non-motor symptoms are more heavily focused on during advanced stages, they occur during all stages of PD<sup>[12,13]</sup>. They have the potential to be early biomarkers for PD, with symptoms such as olfactory dysfunction, sleep problems, constipation, and erectile dysfunction often predating the diagnosis of PD by years<sup>[14,15]</sup>. These symptoms can greatly compromise quality of life (QoL) and daily activities, so typical non-motor treatments are based on improving QoL, with new treatments being developed, but still needing more research because PD treatments heavily focus on motor symptoms<sup>[16]</sup>.

### General pathology

Biochemical studies show a decrease of dopamine (DA) in the caudate nucleus and putamen; PD is therefore considered to be a disease of the neuronal system, which largely involves the nigrostriatal dopaminergic system<sup>[2]</sup>. This disease is identified on the premise of two considerable pathological processes: early selective loss of dopamine neurons, and the buildup of Lewy bodies (LBs) made up of  $\alpha$ -synuclein that become misfolded and accumulate in a number of body systems of Parkinson's patients<sup>[1]</sup>.

The central nervous system is composed of groups of various nerve cells which form complex interactions that allow for skillful movement. The substantia nigra located in the midbrain is of essential importance to PD, as nigral neurons give rise to an extensive axonal network which innervates the basal ganglia.

Liberation of dopamine, a neurotransmitter, by neurons of the substantia nigra allows for communication with neurons of the basal ganglia. Fine tuning of an organism's movements is possible due to this biochemical interaction. Substantia nigra neurons degenerate progressively, leading to lowered levels of dopamine available for neurotransmission in the corpus striatum. This makes Parkinson's a neurological disorder in which movement is affected<sup>[17]</sup>. Resting tremor, rigidity, declining balance and motor coordination, and bradykinesia, which is characterized by a creeping slowness of voluntary movement, are all movement-related symptoms of PD<sup>[17]</sup>.

Dopamine has indirect roles in the striatum, which decreases cortical excitation of striatal neurons<sup>[18]</sup>. Boosts in the physiological state of corticostriatal glutamatergic transmission may possibly be an effect of Parkinsonism impairment of dopaminergic neurotransmission<sup>[19]</sup>. Furthermore, this may consequently emphasize the imbalance between subsets of striata neuronal systems that regulate the basal ganglia's functional output<sup>[17,19]</sup>.

LBs are fibrillar aggregates composed majorly of  $\alpha$ -synuclein. LBs and Lewy neurites are pathologically important to Parkinson's as they serve to be a prominent indication of the disease, being actively associated with Parkinson's pathogenesis<sup>[4]</sup>. The formation of LBs has been considered an explanation to the neuronal degeneration that occurs in PD patients since neuronal loss has been found in predilection sites for LBs. Of the 70+ molecules that have been identified in LBs,  $\alpha$ -synuclein is the most prominent<sup>[4,20]</sup>. Immunocytochemistry of this constituent has uncovered that diffuse cytoplasmic staining cultivates into pale bodies, which are anti-ubiquitin antibodies, by compaction<sup>[20]</sup>. The peripheral portion of pale bodies give rise to LBs. This abnormality has been identified in 10% of pigmented neurons in the substantia nigra and over 50% in the locus coeruleus in PD<sup>[20]</sup>. Six genetic PD-associated mutations of  $\alpha$ -synuclein have been discovered<sup>[21]</sup>. Three mutations related to PD have demonstrated acceleration of  $\alpha$ -synuclein aggregation, while an additional three show delay of aggregation kinetics. It is therefore troublesome to provide a unifying mechanism describing how familial PD-associated mutations affect the structure of  $\alpha$ -synuclein, and how their accumulation and function link with PD, as there have been several suggestions pointing in this direction<sup>[21]</sup>. For instance, membrane binding studies propose that a minute number of these PD mutants strongly bind to synthetic membrane vesicles, while others show a weakened ability to bind to the membrane<sup>[21]</sup>. PD mutations have not been shown to drastically alter the toxicity of  $\alpha$ -synuclein oligomers or fibrils, although more recent studies have indicated that the most potent toxic species responsible for PD are oligomers that are formed early on in the disease process<sup>[21]</sup>. p.A30P is the only mutant that has been found to form faster oligomers and slowed the conversion from oligomers to fibrils. It is plausible that every mutation associated with PD alters  $\alpha$ -synuclein biology in various ways, which is possibly responsible for the pathogenesis of this disease<sup>[21]</sup>.

PD pathology affects more than just the dopaminergic nigrostriatal system. Non-motor symptoms can be better explained when examining the effects of multi-system neurodegeneration. Decades of research point to altered cholinergic neurotransmissions. LBs have been found in the neurons of the nucleus basalis of Meynert, the source of cholinergic innervation of the cerebral cortex<sup>[22]</sup>. The basal forebrain complex, which provides the principal cholinergic input of the entire cortical mantle, degenerates in PD and can lead to symptoms such as dementia, depression, or apathy<sup>[22]</sup>. Anosmia and hyposmia are common side effects of PD. While the pathophysiology is not fully understood, it could be related to  $\alpha$ -synuclein deposits in the olfactory bulb, medulla oblongata, anterior olfactory nucleus, and limbic rhinencephalon<sup>[22,23]</sup>. Progressive, non-linear loss also occurs in serotonergic terminals, although slower than the progressive loss seen in dopaminergic terminals. It can lead to both motor and non-motor symptoms such as depression, tremors, weight loss, and visual hallucinations.<sup>[24]</sup> Reduced levels of serotonin and its metabolite are found in the caudate nucleus, hippocampus, brainstem, and frontal cortex<sup>[25,26]</sup>. Additionally, adrenergic neurons are impacted. One study has shown an increase in  $\alpha_1$  and  $\beta_1$  receptors, especially in demented PD patients, and

a decrease in  $\alpha_2$  receptors within the pre-frontal cortex<sup>[27]</sup>. Disruptions in adrenergic pathways may lead to or worsen dementia and depression<sup>[27]</sup>.

### **GBA-associated PD**

Common risk factors for PD are mutations in the glucocerebrosidase (GBA) gene, which is a gene that encodes for the lysosomal enzyme. During a clinical study on patients with Gaucher's disease (GD), a rare lysosomal storage disorder, this risk factor was identified. It has been discovered that mutations in the GBA gene are more prominent than in any other implicated genes, including dardarin (LRKK2),  $\alpha$ -synuclein (SNCA), and parkin (PARKIN2), in the majority of the PD population.

GD is a recessive disorder in which there is a deficiency in the GBA enzyme<sup>[28]</sup>. It typically involves the mononuclear phagocyte system in which the lysosomes within macrophage lineage cells become excessively stored with lipids<sup>[28]</sup>. This disease is induced by bi-allelic variants in the GBA gene, which encodes acid beta-glucosidase (glucocerebrosidase)<sup>[29]</sup>. Manifestations such as hepatosplenomegaly, anemia, thrombocytopenia, and bony involvement are common with this disorder. As of yet, 300 distinct mutations have been pinpointed on this gene. These mutations include point mutations, frameshift mutations, splice-site alterations, and recombinant alleles that embody segments of the pseudogene sequence<sup>[28,30]</sup>. Gaucher patients who develop parkinsonian features, dementia, or both, are amid the more atypical and uncommon Gaucher phenotypes. A group of 17 GD and Parkinsonism patients were described in 2003. The parkinsonian manifestations were aligned with those of sporadic PD. Many of these patients were in their 40s when they experienced the disease onset, and most responded positively to levodopa (L-DOPA)<sup>[28,31]</sup>. The GBA gene in these patients was sequenced and it was discovered that there were 12 different genotypes; the most prominent type being 1 N370S allele, which was found in 14 of the 17 patients, including five N370S homozygotes. Four patients had an autopsy performed on them, which revealed LB inclusions, predominantly in the cerebral cortex and the hippocampus<sup>[28]</sup>.

Research has shown that the onset of motor impairments among GBA mutation carriers occurs 1.7-6.0 years sooner than in those without mutations. Screening showed that GBA mutations were twice as common in PD patients with an early onset (< 50 years) than those with a late onset<sup>[28]</sup>. 951 patients were screened for N370S and L444P that had an onset of PD before 51 years of age and it was discovered that 6.7% were carriers for the GBA mutation, which is equivalent to the prevalence of patients with homozygous or heterozygous PARK2 mutations<sup>[28,32]</sup>. It was also found that GBA mutation carriers developed clinical symptoms earlier than non-mutation carriers when comparing with patients who developed PD before 50 years of age<sup>[28]</sup>.

Analyses from a study screening for GBA mutations found that GBA carriers were primarily male, had greater occurrences of cognitive dysfunction or dementia, and experienced hallucinations more frequently (not associated with drug treatment) when compared to patients without GBA mutations<sup>[28]</sup>. A second study recorded that GBA mutation carriers with PD more frequently suffer dementia than non-carriers<sup>[28,33]</sup>. The UPDRS, mini-mental state examination, and Hoehn and Yahr staging scales did not detect any noteworthy differences in the magnitude of PD manifestations or the rate of disease progression between GBA carriers and non-carriers<sup>[28,34]</sup>. However, several other studies have documented greater rates of cognitive decline, bradykinesia, olfactory dysfunction, and less rigidity correlated with GBA mutations<sup>[28]</sup>. A German PD study found that GBA mutation carriers have higher frequencies of dementia, neuropsychological disturbances, and autonomic dysfunction, when they compared 20 GBA mutation patients with 20 patients without the mutation<sup>[28,35]</sup>.

The exact mechanisms that contribute to GBA-associated Parkinsonism are not fully known. Further studies are necessary to identify these mechanisms and to discover related risk factors that work in adjunction with

GBA and favor the progression of Parkinsonism. Aging has a role in the onset and development of PD. Factors that change during the aging process such as an increase in  $\alpha$ -synuclein cellular concentrations, and declining numbers of lysosomes and poorer lysosomal function may play a part. Much is known about the GBA protein, especially when compared to other genes associated with PD. Considerable therapeutic strategies for the treatment of Gaucher's disease may lead to stabilization of GBA or improvement of enzymatic activity which could influence the development of parkinsonian neurodegeneration. A deeper understanding of this enigmatic protein and its role in the progression of Parkinsonism could improve genetic counseling for those who are GBA mutation carriers and enhance therapeutic approaches for GBA-associated Parkinsonism, possibly altering the treatment of all PD patients<sup>[28]</sup>.

### Early-onset

The incidence of PD increases with age, with an incidence of 0.5 per 100,000 for people below 40 years old compared to the overall incidence of 13.4 per 100,000 for all ages<sup>[36]</sup>. Early-onset PD is the development of symptoms in those below 60 years old. It can be divided further into juvenile PD in those younger than 21, and young-onset PD if between the ages of 21-40<sup>[36]</sup>. Early-onset PD is attributed to genetic factors, rather than environmental<sup>[17]</sup>. Juvenile PD is rare, but worth mentioning. Its genetic mutations can cause further distinct types of PD. For example, the mutation of ATP13A2 causes Kufor-Rekab syndrome, which is a specific juvenile PD that has less than 50 cases reported to date<sup>[36]</sup>. Early-onset PD differs in presentation of symptoms and responsiveness to treatment than late-onset PD<sup>[1]</sup>. With early-onset PD, bradykinesia and rigidity are more likely to be the presenting symptoms, rather than gait disturbance, when initially treated<sup>[1,37]</sup>. Early-onset has a slower disease progression and is more likely to develop L-DOPA-related dyskinesia, so dopamine agonists are frequently chosen as the initial treatment options over L-DOPA<sup>[1]</sup>. However, new evidence suggests that L-DOPA does not necessarily need to be avoided in treatment of early-onset PD<sup>[38]</sup>. This will be discussed in the dopaminergic medications section below.

### Tremor-dominant vs. non-tremor dominant responsiveness to L-DOPA

PD is a disorder with various motor subtypes, but few neuroimaging studies have examined the variable effects of L-DOPA treatment on the different motor sub-classifications of Parkinson's. One study by Mohl and colleagues investigated L-DOPA-induced differences in neural activation between tremor dominant (TD) PD patients and posterior instability/gait difficulty (PIGD) PD patients. They utilized neuroimaging by the use of fMRI to investigate task-induced activation and connectivity in the cortico-striatal-thalamo-cortical (CSTC) motor circuit before and after L-DOPA deliverance in 21 age- and sex-matched healthy controls, fourteen TD patients, and twelve PIGD patients. Each subject executed a right-handed, paced, finger-tapping task. There was greater activity within the left putamen in the PIGD patients on L-DOPA compared to the TD patients on L-DOPA and the healthy control group. This hyperactivation within the left putamen induced by L-DOPA during the finger-tapping task, however, was not accompanied by an upsurge in effective connectivity between the left posterior putamen and CSTC motor network. This finding implies a rooted pathophysiological discrepancy between motor subtypes of PD that can be evoked using a dopaminergic medication during a motor activity. Relative to the healthy control subjects, PD patients not taking medication displayed hypoactivation of the left primary motor cortex when performing the tapping task. To further investigate whether this data is applicable to one or both of the subtypes examined in the study, researchers separately compared TD patients off of medication and PIGD patients off of medication to healthy controls. It was discovered that hypoactivation of the motor cortex was greatly driven by the group of TD patients off of medication. Furthermore, PD patients on medication did not show any changes in activation within the primary or secondary motor cortices when contrasted with the control group<sup>[39]</sup>.

Putamen changes are associated with the symptomatology that defines motor subtypes of PD<sup>[39]</sup>. SPECT studies discovered a link between putaminal uptake of dopamine transporter (DaT) tracer and poorer rigidity, in addition to more noticeable dopaminergic loss in the posterior putamen in non-TD patients and

mixed subtype patients relative to TD patients<sup>[39,40]</sup>. This SPECT study, together with the study conducted by Mohl and colleagues that evidenced an increase in left putamen activity by L-DOPA during finger-tapping task in PIGD patients only, implies plausible roles of the putamen in phenotypic PD subtype manifestations<sup>[39]</sup>.

Furthermore, L-DOPA resulted in divergent tapping-induced coupling responses within the motor network in PIGD and TD PD patients. These findings could not be attributed to variation in the stage or duration of the disease. When comparing TD patients on medication to TD patients not on medication, there was a noteworthy increase in effective connectivity between the left posterior putamen and other motor network areas, whereas PIGD patients on and off medication did not show any compelling changes. Underlying pathophysiological disparity between recognizable PD motor subtypes may explain the differential responses of these subtypes to L-DOPA<sup>[39]</sup>.

### Treatment Approaches

Though the exact cause of Parkinson's disease has not been identified, treatment discoveries have been progressive. There is no known cure for the disease, so treatments seek to manage symptoms rather than prevent or slow the progression of the disease. Treatments can vary from drugs, surgeries, therapy, or a combination of different treatments [Table 1]. They must also be adjusted throughout the course of the disease, as some common treatments, such as L-DOPA lose effectiveness over time<sup>[1]</sup>. Treatment of PD using available drugs has positive symptomatic effects; however, there are no disease-modifying or neuroprotective therapies available to slow the progression of the disease<sup>[1,41]</sup>. Therefore, treatment begins at the discretion of the patient and the physician when symptoms begin to impair function or provide social embarrassment. No one drug is more beneficial than the other for initial treatment, but instead the disease itself must be looked at in terms of severity and time of onset<sup>[42]</sup>. PD is a disease that affects multiple neural pathways in the brain. While L-DOPA may treat motor problems caused by low dopamine levels, it will not treat motor problems caused by low acetylcholine levels in other pathways. Additionally, each subtype responds differently to drugs. It is up to the discretion of the doctor to choose a plan that works for an individual patient based on responsiveness and symptoms.

## DRUG TREATMENTS

### Dopaminergic medications

Dopaminergic medications are the typical treatment method for motor symptoms in PD, and L-DOPA, the most potent anti-parkinsonian drug currently available, remains the "gold standard" for PD therapy. Because the lack of dopamine available for communication in the nigrostriatal pathway is at the root of many PD symptoms, specifically movement-based ones, dopaminergic medications are used to help increase or mimic dopamine levels. Dopamine does not easily pass through the blood brain barrier, but its precursor, L-DOPA can<sup>[43]</sup>. It is metabolized in the small intestine and is converted to dopamine by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase (COMT), which can then be stored in the nigrostriatal terminals. In contrast, dopamine agonists act directly on postsynaptic receptors, mitigating the need for dopamine production<sup>[43]</sup>.

Responsiveness to L-DOPA occurs in 80% of patients with idiopathic PD, reducing bradykinesia and rigidity. However, it is ineffective or unsatisfactory at treating several prominent PD symptoms: posture and gait problems, speech problems, freezing, autonomic dysfunction, cognitive disorders, affective disorders, and sleep problems<sup>[1]</sup>.

As previously mentioned about early-onset PD, there are concerns about L-DOPA-related dyskinesia. While dyskinesia is correlated with L-DOPA usage, the disease itself (PD) and a pulsatile drug delivery are both required for dyskinesia to develop. L-DOPA does not usually induce dyskinesia in Parkinsonism with post-

**Table 1. Summary of different treatment options with their pros and cons**

Treatment Option	Summary	Pros	Cons
Drug Treatments		Limited to no invasive treatment required	May lose effectiveness over time Various side effects for each drug
Dopaminergic Medications	Dopamine agonists taken orally or through injection	<ul style="list-style-type: none"> <li>Current “gold standard for treatment”</li> <li>High responsiveness (80%) in idiopathic PD</li> <li>Favored treatment for late-onset PD</li> <li>May affect both motor and non-motor side effects</li> <li>Most patients ultimately take dopamine agonists as the disease progresses and other treatments stop being effective</li> </ul>	<ul style="list-style-type: none"> <li>Less favored for early-onset PD treatment due to levodopa-related dyskinesia</li> <li>Levodopa requires increasing dosage over time “on-off” fluctuations with oral medication</li> <li>Irritation or problems at pump site for injection method</li> </ul>
MAOIs, inhibitors and antagonists	Inhibit breakdown of levodopa and dopamine through oral drugs	<ul style="list-style-type: none"> <li>Do not need increased dosage over time</li> <li>May help with cognitive decline in later stages of PD</li> <li>Milder side effects than dopaminergic drugs</li> <li>May treat L-DOPA-related dyskinesia</li> </ul>	<ul style="list-style-type: none"> <li>Lack extensive effects on symptoms for late stage PD</li> <li>Must be supplemented with a group of drugs for some treatments, such as COMT inhibitors</li> </ul>
Anticholinergics	Reduce acetylcholine activity at choline receptors through oral drugs	<ul style="list-style-type: none"> <li>Rapid absorption, used for tremor-predominant PD</li> <li>Can be a monotherapy in early stages</li> </ul>	<ul style="list-style-type: none"> <li>Less tolerance in elderly patients</li> <li>Lack of testing in elderly patients</li> <li>New testing may show cholinergics, rather than anticholinergics, may improve PD symptoms</li> <li>Largely replaced by dopamine agonists in current treatment regimes</li> <li>Little pharmacokinetic information</li> </ul>
Neurotrophic Factors: GDNF	Small natural proteins, specifically glial cell line-derived neurotrophic factor (GDNF), delivered through an implantation in the brain	<ul style="list-style-type: none"> <li>Improvement of parkinsonian symptoms</li> <li>Increased striatal dopamine levels</li> <li>Prevention from neurotoxic damage of dopaminergic neurons in the midbrain and noradrenergic neurons in the locus coeruleus</li> </ul>	<ul style="list-style-type: none"> <li>Difficult delivering this NTF to brain cells across the BBB</li> <li>Studies show differing outcomes on the effectiveness of GDNF on symptomatic relief</li> <li>Requires more research</li> </ul>
Nanomedicine	Modification of existing drugs to improve delivery method	<ul style="list-style-type: none"> <li>Greater delivery through the blood brain barrier or circumventing it</li> <li>Less drug lost in peripheral tissue, increasing effectiveness and decreasing side effects</li> <li>Growing field with investigations into protective factors and imaging improvements</li> </ul>	<ul style="list-style-type: none"> <li>Relatively new field that requires more testing before being a standard practice</li> </ul>
Surgical Treatments		Can have high effectiveness with long-term results	Most invasive of the treatment methods Some methods and side effects are irreversible
Ablative Surgery	Incision into the global pallidus, thalamus, or subthalamic nucleus either bilaterally or unilaterally	<ul style="list-style-type: none"> <li>High-effectiveness, relieving rigidity, hypokinesia, and tremors.</li> </ul>	<ul style="list-style-type: none"> <li>Irreversible procedure, may have permanent side effects</li> </ul>
Deep Brain Stimulation	Implant that stimulates the basal ganglia through high frequency electrical stimulation	<ul style="list-style-type: none"> <li>Bilateral DBS is likely safer than bilateral ablative surgeries</li> <li>Established treatment for advanced PD</li> <li>Can improve both motor and non-motor symptoms</li> <li>Equal improvement compared to L-DOPA for tremor, bradykinesia and rigidity</li> <li>Closed-loop DBS is being investigated to reduce side effects and allow greater feedback</li> <li>Effective at minimizing “off” episodes</li> <li>Benefits can last 10+ years in some individuals</li> </ul>	<ul style="list-style-type: none"> <li>Conventional DBS is open-loop, not allowing for feedback and patient adjustment</li> <li>Less effective for reducing gait, balance, and speech symptoms</li> <li>May include dysarthria, imbalance, and dyskinesia</li> <li>Limited battery life</li> </ul>
Transplantation and Gene Therapy	Transplantation of stem cells into the striatum, insertion of non-disease and disease modifying transgenes	<ul style="list-style-type: none"> <li>Can generate long-lasting improvement and replace diseased neurons</li> <li>Can treat PD at a genetic level, correcting dopamine pathways</li> </ul>	<ul style="list-style-type: none"> <li>Must consider ethical bounds for embryonic stem cell use</li> <li>Developing fields that require more research, especially human testing</li> </ul>
Therapy		Can address multiple symptoms at once, both motor and nonmotor Noninvasive treatment	Usually requires other forms of treatment in addition to therapy

Physical Therapy	Addresses mobility and motor-related symptoms through physical training	<ul style="list-style-type: none"> <li>• Can greatly increase quality of life</li> <li>• Treat multiple symptoms at once</li> <li>• Multiple forms of PT exist, allowing for patient-specific care that adapts</li> </ul>	<ul style="list-style-type: none"> <li>• May require other treatments, especially as the disease progresses</li> <li>• Limited by patient involvement and motivation</li> </ul>
Occupational Therapy	Help patients maintain work, leisure, and self-care activities for as long as possible	<ul style="list-style-type: none"> <li>• Promotes independence</li> <li>• Allows one to engage meaningfully</li> <li>• Addresses social and environmental side effects and factors</li> </ul>	<ul style="list-style-type: none"> <li>• Usually requires PT with it, as well as additional treatments</li> <li>• Does not address PD at a physiological level</li> <li>• Limited by patient involvement and motivation</li> </ul>
Speech Therapy	Improves speech through voice exercises	<ul style="list-style-type: none"> <li>• Focuses on a single parameter but improves multiple voice symptoms</li> <li>• Improves quality of life</li> </ul>	<ul style="list-style-type: none"> <li>• Helpful for only speech disorders</li> </ul>
Cognitive Behavioral Therapy	Management of a symptom through behavioral training methods	<ul style="list-style-type: none"> <li>• Alternative for symptoms commonly treated with drugs, helping to reduce complications</li> <li>• Few side-effects</li> <li>• As effective as drugs in treating insomnia</li> <li>• May be done remotely</li> </ul>	<ul style="list-style-type: none"> <li>• Cannot be double-blinded testing</li> <li>• Manages only one symptom</li> <li>• Needs more testing</li> <li>• Dependent on patient motivation</li> </ul>

synaptic involvement, and intestinal gel delivery has shown to reduce pre-existing dyskinesia. Therefore, it may be more appropriate to view dyskinesia as a result of the method of administering levodopa rather than an intrinsic effect of L-DOPA itself<sup>[38]</sup>.

With late-onset PD, there is a greater risk of adverse neuropsychiatric effects from dopamine agonists, so L-DOPA is favored as an initial treatment. Both types of PD require adjustments to medication as the disease progresses, as those patients who use dopamine agonists initially often need to start taking L-DOPA after two to five years; L-DOPA too loses its effectiveness over time<sup>[1]</sup>.

Along with managing motor symptoms of PD, non-motor symptoms such as depression can also be managed with dopamine agonists. Drugs like Pramipexole are effective and clinically useful for managing depression and depressive symptoms for those with PD. However, not all dopamine agonists are effective; Rotigotine, for example, is ineffective and investigational in practical application<sup>[16]</sup>. Most drugs that treat non-motor symptoms use other neurotransmitters than dopamine<sup>[44]</sup>. Treatment of depression with dopamine agonists should not be universal, but specific to the drug and the patient's needs<sup>[16]</sup>.

Despite being the “gold standard” for PD treatment, L-DOPA does not come without a series of problems. It is unknown whether the symptomatic benefits of Levodopa have an association with neurotoxic effects and long-term deterioration. It, however, has long term complications, the most problematic being: wearing-off, dyskinesias, freezing episodes, and “on-off” fluctuations that are impossible to predict<sup>[45]</sup>. Within five years of chronic L-DOPA treatment, 40%-50% of patients will develop dyskinesias and motor fluctuations. After 10 years, that number increases to 70%-80% of patients<sup>[1]</sup>. L-DOPA's effectiveness also declines in advanced PD due to fluctuating medication periods and levodopa's short half-life<sup>[1]</sup>. Patients are commonly required to increase dosage amounts as well as the frequency of doses, requiring a dose every 2-3 h, for example<sup>[44]</sup>. With the resulting increase medication dosage, presentation of dyskinesias also increases.

Alleviation of PD symptoms from L-DOPA can also make it difficult to accurately assess the patient's honest condition, making the progression of the disease troublesome to supervise. In order to make assessments of the disease progression, or deterioration, administration of L-DOPA must be withdrawn for at least two weeks. This option is not practical, especially in advanced stages of PD. The search for biological surrogate markers is underway, and there have been developments of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) techniques, which have shown compelling correlations with PD's global severity<sup>[45]</sup>. In addition to finding new biological



surrogate markers, alternatives and better management of L-DOPA use are being investigated. Continuous dopaminergic stimulation is needed for those with advanced PD, which can be provided through levodopa-carbidopa intestinal gel and deep brain stimulation as an alternative for oral L-DOPA<sup>[1]</sup>.

Levodopa-carbidopa intestinal gel, also referred to as Duodopa, is an option for those with advanced PD, compared to oral L-DOPA, with the intestinal gel showing less motor fluctuations and dyskinesias, though they are not completely eliminated. The gel is injected into the jejunum, with the gel delivering a continuous dosage of levodopa-carbidopa equivalent to the oral L-DOPA dose. There is faster absorption without the concern of reduced absorption<sup>[1]</sup>. Because the drugs are released continuously, “off” periods are reduced and “on” periods increased<sup>[46]</sup>. In one study, 90% of patients had an improved QoL<sup>[47]</sup>. Nocturnal sleep habits improved in all patients who switched to levodopa-carbidopa gel injections, with improvements in motor symptoms at night, PD symptoms at night, and disturbances during sleep. Daytime drowsiness also improved<sup>[48]</sup>. Improvements in other non-motor symptoms have been observed including attention, memory, gastrointestinal, urological, and pain<sup>[49]</sup>. A benefit of levodopa-carbidopa intestinal gel compared to alternatives for advanced PD is that there is no age limit for its administration. Adverse effects are mostly due to technical problems such as dislocation, kinking, obstruction and breakage of the duodenal catheter<sup>[46]</sup>.

Apomorphine is a non-selective dopamine agonist that activates both D1 and D2 receptors, is used as a drug for PD patients suffering from motor fluctuations, and possibly has positive effects on non-motor symptoms. Unlike other antiparkinsonian agents, it is the only one comparable to L-DOPA in its capacity to control motor symptoms<sup>[50]</sup>. Use of apomorphine is not typically age-limited, but it is limited by a need for confirmed levodopa-responsive PD. Apomorphine is an option for patients with “off” periods including delays in effects when taking orally administered medications like L-DOPA, or “off” periods when waking up. Intermittent or continuous infusion administered subcutaneously have shown to be the most effective and bearable application processes<sup>[50]</sup>. Intermittent infusion is administered by injection via pen for rapid relief of “off” fluctuations and end-of-dose biphasic dyskinesia. Continuous infusion is administered through a modified insulin pump, most commonly dispensing in a 12-16 h regimen, although it can be given throughout the 24 h and need not be discontinued at night. This can reduce the “off” times at night<sup>[46]</sup>. Adverse side effects may include nodules at the injection side, which can be seen in up to 70% of patients, bruising, itching, or pain. An advantage of apomorphine for those with advanced PD is that it is less invasive than deep-brain stimulation or levodopa-carbidopa intestinal gel<sup>[50]</sup>.

It is suspected that the frequent pain experienced by patients with PD could be partly due to central modification of nociception. A randomized, controlled, double-blind study of 25 PD patients by Dellapina *et al.*<sup>[51]</sup>, compared apomorphine versus placebo to test their effects on pain thresholds and pain-induced cerebral activity. Apomorphine was not found to have any determinable change on subjective or objective pain thresholds, or pain activation profiles when compared with placebo. In conclusion, apomorphine has no effect on pain processing in patients with PD, suggesting thereby that other monoamine systems may be involved<sup>[51]</sup>.

### **Monoamine oxidase inhibitors, Catechol O-methyltransferase inhibitors, and N-methyl D-aspartate receptor antagonists**

Monoamine oxidase inhibitors (MAOIs), like rasagiline or selegiline, and COMT inhibitors, like entacapone, work to inhibit the breakdown of dopamine and L-DOPA to prolong their effects. MAOIs reduce the amount of dopamine broken down in the synapse. COMT inhibitors prevent COMT from prematurely converting L-DOPA into dopamine. It reduces peripheral loss of L-DOPA before it can reach the brain<sup>[1,43]</sup>. Patients with mild symptoms may be treated with MAOIs first, due to their milder side effects, less frequent doses and to delay the treatment of dopaminergic drugs. They may also be used in later stages

to reduce specific symptoms such as tremor or dyskinesias<sup>[1,42]</sup>. MAOIs are dosed 1-3x daily throughout the course of the disease, not needing to increase the dosage over time, like L-DOPA<sup>[44]</sup>. Treatment with cholinesterase inhibitors, such as rivastigmine, may help with cognitive decline or hallucinations/delusions associated with advanced or later stages of PD<sup>[45]</sup>. Putative N-methyl-D-aspartate (NMDA) receptor antagonists, like amantadine and memantine, are also drugs taken as adjuncts to other treatment<sup>[1]</sup>. They block acetylcholine and NMDA receptors, which has two effects: the first is that they synergize with dopaminergic agents, enhancing release and turnover of dopamine in the striatal neurons; second, PD disrupts glutamatergic transmissions causing an overactivation of NMDA receptors, which can cause worsening dyskinesias<sup>[52]</sup>. Agonists reduce the amounts of abnormal glutamate signaling in the subthalamic nucleus<sup>[52]</sup>. In one study, amantadine was able to reduce dyskinesia severity by 60% in advanced stage PD, when taken with regular doses of L-DOPA<sup>[53]</sup>. Amantadine extended release is currently the only FDA-approved medication for the treatment of levodopa-related dyskinesia, allowing for greater sustainability of L-DOPA therapy and reducing the “off” time<sup>[54]</sup>. No existing drugs have extensive effects on symptoms that develop in the later stages of this disease, such as postural instability, dysphagia, dysphonia, dyskinesias, as well as constipation<sup>[45]</sup>. NMDA receptor agonist may possibly be neuroprotective. They can prevent disease progression by inhibiting glutamatergic-mediated excitotoxicity and stimulate synaptogenesis/neurotrophic release<sup>[52]</sup>.

### Anticholinergics for early on

The first pharmacological agents used in PD therapy were anticholinergic drugs<sup>[55]</sup>. They reduce the activity of acetylcholine by acting as antagonists at choline receptors, hoping to restore the balance between dopamine and acetylcholine levels that was disturbed by PD<sup>[56]</sup>. These drugs have largely been replaced by L-DOPA and other centrally acting dopaminergic agonists, but they still remain available for use in the treatment of PD. Benztropine, biperiden, diphenhydramine, ethopropazine, orphenadrine, procyclidine, and trihexyphenidyl are included in this therapeutic class of drugs, though there is little pharmacokinetic information available on them because of their low plasma drug concentrations<sup>[55,57]</sup>. Typically, anticholinergic drugs have a greater role in tremor-predominant PD and can be a monotherapy in early stages, but are usually done in adjunct with L-DOPA or other prescribed medications<sup>[56]</sup>.

Oral administration of this drug class has rapid absorption in humans. There is variability in the oral bioavailability among the various drugs of this class, ranging anywhere from 30% to 70%. Volume of distribution in humans and animals of these drugs is large, and tissue distribution is rapid. A characterization of these drugs is their relatively low clearance when compared to hepatic blood flow. These drugs appear to be broadly metabolized, chiefly to N-dealkylated and hydroxylated metabolites<sup>[55]</sup>. There is less tolerance of these drugs in the elderly than in younger patients. Additionally, these drugs may be avoided in the elderly because of an increased risk of confusion<sup>[56]</sup>. Since the majority of studies have been restricted to young healthy volunteers who are given single doses, there is a lack of pharmacokinetic information regarding these drugs in the elderly. Furthermore, the shortcoming of information for multiple dose administration and administration in the elderly may be a possible deterrent in the safe and competent use of these pharmaceuticals in PD patients<sup>[55]</sup>.

It should be noted that while anticholinergics remain a viable drug treatment, there are studies that point to the possibility of cholinergic therapy helping to manage mobility problems in PD by looking at the pedunculopontine nucleus-laterodorsal tegmental complex (PPN). A key role of the PPN is maintenance of balance, and PPN dysfunction can cause impaired postural control and gait in PD<sup>[22]</sup>. Anticholinergic medicine can increase the incidence of falling in the elderly. Additionally, the loss of CNS cholinergic neurons can worsen balance. Preliminary data of a controlled, small study shows that PD patients that are given donepezil, a central cholinesterase inhibitor, fell half as often as the control group<sup>[58]</sup>.

## Neurotrophic factors

Nerve cells require neurotrophic factors (NTFs), which are small natural proteins, for their development and continued survival. In addition, NTFs help maintain the morphological and functional phenotype of nerve cells. Neuronal networks require the release of NTFs at the target structures. NTFs are taken up by the nerve terminals and moved retrogradely to the soma of the projecting neurons for their formation and preservation. This is described by the “neurotrophic hypothesis”. Neuronal survival and phenotype specification is stimulated by the induction of a gene upon the arrival of NTFs at the nucleus. There have been several proteins that have been classified as NTFs based on the effects they have on neuronal survival, differentiation, maturation of electrophysical properties, and plasticity. The functional roles of NTFs provide promising possible benefits in the treatment of neurodegenerative diseases, including PD<sup>[59]</sup>. Glial cell line-derived neurotrophic factor (GDNF) is one of the more closely related NTFs associated with PD as a result of the potent trophic action it has on cultured dopaminergic neurons<sup>[59,60]</sup>. Production of GDNF is done by striatal neurons and is required for the sustenance of adult nigrostriatal dopaminergic neurons and other central and peripheral nuclei affected in PD<sup>[59,61]</sup>. Exogenous administration of GDNF has also shown neurotoxic damage preventative abilities of dopaminergic neurons in the midbrain, and noradrenergic neurons in the locus coeruleus<sup>[59,61,62]</sup>. Evidence of GDNF and its effect on the latter neurons implies that the stimulation of endogenous GDNF generation and/or administration of exogenous GDNF could serve as competent therapeutic strategies for PD<sup>[59,63,64]</sup>.

Different human studies testing the effects of striatal delivery of GDNF through the permanent implantation of a cannula have demonstrated varying degrees of symptomatic relief<sup>[62]</sup>. Some subjects experienced incremental improvement, such as the study conducted by Gill and colleagues, while other studies showed no evident benefits<sup>[32,62,65]</sup>. There is much variability in the outcomes of documented studies: some have recorded antibody development in response to the administration of recombinant human GDNF, a randomized trial detailed reactions to the placebo, and one study noted that subjects experienced strong adverse effects to intraventricular delivery of GDNF<sup>[33,34,62,65]</sup>. In addition, deliverance of GDNF to brain cells across the blood brain barrier poses as a hindrance to the use of this approach as a PD treatment, suggesting that the simple administration of the NTF protein may not be a plausible option<sup>[35]</sup>. Alternative studies are needed to uncover ways to sustainably exploit the benefits of the potent trophic action that GDNF has on dopaminergic neurons<sup>[62]</sup>.

GDNF is necessary for the survival of adult catecholaminergic neurons. The onset of PD due to the loss of dopaminergic neurons has been linked to GDNF signaling failure. A study conducted by Hadaczek and colleagues showed weakened GDNF signaling in neurons that were deficient in ganglio-series gangliosides (glycosphingolipids that contain sialic acid), and renewal of this dampened signaling with LIGA20, which is a membrane permeable ganglioside analog of GM1<sup>[36,66]</sup>. GM1 is a commonly studied ganglioside that is shown to be associated in situ with the GDNF receptor protein components, GFR $\alpha$ 1 and RET, which are essential for the ternary receptor complex<sup>[36]</sup>. Whole or partial deficiency of GM1 due to interruption of the B4galnt1 gene in mice resulted in the development of PD symptoms. Inadequate levels of tyrosine phosphorylated RET were observed in PD patients that had severely deficient GM1 in nigral neurons. In addition, PD patient brains exhibited significantly lower levels of GM1 in the occipital cortex when compared to age-matched controls. This implies that decreased systemic GM1 may be a risk factor in PD<sup>[66]</sup>.

## Nanomedicine

Nanomedicine and the manipulation of compounds on the nanometric scale is being investigated for the improvement of drug delivery systems, specifically to improve drug bioavailability, half-life, or achieve more sustained levels of circulation. The most widely used approach is to increase the ability of drugs to be transported across the blood brain barrier<sup>[67,68]</sup>. This is particularly important with L-DOPA and dopamine agonists because the process with which they are mediated through the blood brain barrier

can also occur in peripheral tissues<sup>[67]</sup>. Intranasal delivery allows for drug transport through the olfactory and trigeminal pathways, circumventing the blood brain barrier<sup>[69]</sup>. Nanoparticles accelerate this method of absorption. However, this is not the only delivery system being investigated for nanotechnology. With drugs such as apomorphine, the drug is associated with a lipid-based manipulated nanomolecule, trapping the drug inside or adhering it to itself. When taken orally, it stimulates chylomicron formation and allows for better systemic absorption by the lymphatic system<sup>[67]</sup>. Promising results from a study showed 12- to 13-times higher bioavailability using solid lipid nanoparticles compared to standard oral apomorphine. However, this study and a majority of similar studies have only been performed on rats and while they have promising results, there is a need for more research before they can be standard practice<sup>[70]</sup>. This is the main limitation for nanomedicine. It is a new and developing field, so many of the studies and drug delivery methods have not reached human testing yet and will need years before being viable practices in the field.

Nanomedicine is also being looked at for more than just drug delivery systems for PD. Studies are investigating the delivery of neuroprotective factors, enzymes, antioxidants, growth factors, and inhibition of  $\alpha$ -synuclein aggregation. Nanomedicine is also focusing on areas including imaging and detection improvements, as well as deep brain stimulation<sup>[67]</sup>.

## **SURGICAL TREATMENTS**


There are three major surgical treatments for PD: ablative surgery, deep brain stimulation (DBS), and grafting fetal mesencephalic cells into the striatum.

### **Ablative surgery**

Ablative surgery is the oldest of the three major surgical treatments and holds the greatest risks. Pallidotomy, thalamotomy, and subthalamotomy are available surgeries<sup>[71]</sup>. Locations of each surgery and the pathways that are disrupted can be seen in [Figure 1](#). Because of the loss of dopaminergic innervation, the internal globus pallidus and substantia nigra reticulata have hyperactivity leading to excessive inhibitory output<sup>[73,74]</sup>. The inhibitory output interferes with the movement-related center in the thalamus and generates hypokinetic PD symptoms<sup>[73]</sup>. Ablative surgery tries to alleviate these symptoms by creating a lesion within the internal globus pallidus, thalamus, or subthalamic nucleus to stop the overactive pathway either near the start, as in pallidotomies, or further down the line in thalamotomies [[Figure 1](#)]<sup>[74]</sup>. In one study, stereotactic posteroventral pallidotomies were performed on 38 patients, giving complete or almost complete relief of rigidity and hypokinesia in 92% of patients<sup>[75]</sup>. As well, 32 patients had suffered tremors before the surgery, and 81% of them had complete or almost complete relief of tremor, post-surgery. Gait and speech volume also saw improvement. However, seven patients (roughly 18%) had complications, with six patients presenting with permanent partial homonymous hemianopsia; one of those patients also had transient dysphagia and facial weakness. The other patient developed transitory hemiparesis 1 week after the surgery<sup>[75]</sup>. Thalamotomy is an option for patients that have long-standing tremor as the main clinical manifestation, and it cannot be controlled by drugs. Thalamotomy is less common than pallidotomy, with less than 5% of patients having the thalamus as the preferable target for thalamotomy or DBS<sup>[76]</sup>. Ablative surgeries have lost prevalence because of concerns over high incidence of side-effects with bilateral ablative procedures<sup>[71]</sup>. At experienced centers, unilateral pallidotomy is equally safe as unilateral DBS, though bilateral DBS is likely safer than bilateral pallidotomy. Therefore, while DBS may be more common now, pallidotomy and other ablative surgeries are still viable options when DBS is not available nor feasible<sup>[77]</sup>.

### **Deep brain stimulation**

Deep brain stimulation (DBS) developed as an alternative to risky bilateral ablative surgeries. It is applied in the internal globus pallidus, subthalamic nucleus, and thalamus<sup>[71]</sup>. It is similar to ablative surgeries in terms of the pathway and symptoms that DBS is trying to mitigate. Conventional DBS is open-loop, with the implants delivering electrical impulses continuously and without feedback<sup>[74]</sup>. It is an established



**Figure 1.** An overview of the basal ganglia neuroanatomy and primary motor circuits. Ablative surgery options include pallidotomy - destroying the globus pallidus (GPE, GPI in maroon and pink, respectively), thalamotomy - destroying the thalamus (purple), and subthalamotomy - destroying the subthalamic nucleus (STN, blue). Procedures can either be bilateral or unilateral and are done to reduce excessive inhibitory output from the internal globus pallidus (pink) and substantia nigra reticulata (green), and their respective pathways shown in red. Image provided by Harris et al.<sup>[72]</sup> 2020

treatment for advanced stage PD, improving motor symptoms both in the long and short term<sup>[78]</sup>. DBS is effective at minimizing instances of “off” episodes that tend to occur more frequently throughout the day in patients with more progressed stages of medically treated PD. There are variable effects on motor symptoms and non-motor symptoms such as postural and gait disturbances, cognitive decline, sleep, swallowing, and speech or micturition disturbances<sup>[79]</sup>. Controlled studies using large and randomized groups have displayed comparable motor benefits between the subthalamic nucleus (STN) and the globus pallidus pars interna (GPi), which are two of the most prevalent targets for DBS. However, DA replacement pharmaceuticals can be decreased following STN DBS, whereas there are less cognitive and mood side effects from GPi DBS<sup>[80]</sup>. In addition, gait instability and freezing may be improved from targeting the pedunculopontine, as evidence suggests<sup>[81,82]</sup>.

DBS involves a delivery of unceasing high frequency electrical stimulation to the basal ganglia. The mechanism of this therapy is not fully understood, but it is known that there is an interference with pathological and physiological neural circuitry<sup>[79]</sup>. High-frequency stimulation of distinct targets in the brain resembles functional effects of a lesion and has inhibitory effects on neuronal activity. Prospective mechanisms include high-frequency patterns obscuring encoded information, suppression of abnormal beta oscillations, stimulation of inhibitory gamma-aminobutyric acid (GABAergic) afferents to the nucleus in focus, efferent projections or passing fibers, and the inhibition of neurotransmitter and hormone

production or release. DBS mechanisms are intricate as excitation or inhibition of neural elements may occur, dynamic equilibrium states are attained, and differing forms of neural plasticity are established<sup>[83]</sup>. Internal pulse generators (IPGs) are able to record and store local field potential and multiple targets concurrently, allowing physicians and researchers to more advantageously understand the pathophysiology of PD and the mechanism by which DBS mitigates symptoms. Subthalamic nucleus (STN) and the globus pallidus pars interna (GPi) are the most prevalent targets for DBS. Common motor benefits between these targets have been indicated by large, randomized, controlled studies. Dopamine replacement drugs can generally be decreased following STN DBS, while GPi DBS can lead to less adverse cognitive and mood effects<sup>[79]</sup>.

Response to DBS is equal to the best responses of L-DOPA, improving levodopa-responsive symptoms of tremor, bradykinesia, and rigidity. Gait, balance, and speech are less likely to improve<sup>[1]</sup>. In fact, stimulation-induced side effects include dysarthria, imbalance, and dyskinesia. Another limitation is a limited battery life<sup>[78]</sup>. There is no definitive duration that DBS remains effective, but it can have benefits for at least 10 years in some<sup>[1]</sup>.

While conventional DBS is a successful treatment, closed-loop DBS is being investigated as a solution around the limitations caused by open-loop DBS, by being able to adjust stimulation in real time according to the patient<sup>[78]</sup>. In contrast to open-loop DBS which embeds lasting electrodes into the basal ganglia and provides uninterrupted electrical stimulation independent from any feedback, closed-loop DBS delivers electrical stimulation as a function of neuronal activity, all of which is documented and evaluated online<sup>[74]</sup>. It allows for more efficient and long-term improvements for PD treatment and has the potential to reduce or remove adverse effects in 19% of PD patients treated with subthalamic nucleus DBS according to one study<sup>[84]</sup>.

### **Surgical therapies with transplantation and gene therapy**

Cell transplantation is regarded as a potential future PD treatment. There have been trials using autologous and non-autologous cells. Human embryonic stem cells and induced pluripotent stem cells are few of the cells that have been included in these transplantation studies. One of the concerns with cell transplantation using stem cells is the ethical bounds that must be considered<sup>[79,85]</sup>.

Since the first clinical trial in 1987 involving the transplantation of dopaminergic- neuron-rich human fetal mesencephalic tissue into PD patients' striatums, more research has aimed to explore whether the grafted dopaminergic neurons will live and form connections in the brain, if the patient's brain can harmonize and make use of the grafted neurons, and if the grafts can generate significant clinical improvement<sup>[86]</sup>. Clinical trials with cell therapy intend to discover if there are long-lasting improvements following restoration of striatal DA transmission by grafted dopaminergic neurons. Experimental data from rodents and nonhuman primates show that fetal ventral mesencephalon intrastriatal grafted DA neurons demonstrate many morphological and functional characteristics of normal DA neurons. Significant improvements of PD-like symptoms in animal models have been demonstrated after successful reinnervation by the grafts. Dopaminergic grafts can reinnervate the striatum in the brain, restore regulated release of DA in the striatum, and can become functionally integrated into neural circuitries<sup>[86]</sup>.

A new area that is being explored in the treatment of PD is gene therapy. Both non-disease and disease modifying transgenes are being researched. Non-disease modifying transgenes target GABA and dopamine synthesis pathways. Disease modifying transgenes have the potential to slow the progress of the disease. Both transgenes are too early in trials to be conclusive but offer promising results<sup>[87]</sup>. Gene therapies address only the motor symptoms, not the non-motor symptoms<sup>[88]</sup>.

Treatment of PD by gene therapy requires an appropriate delivery method for the synthesized nucleic acid: viral or nonviral. Vector choice considerably determines the delivery technique used. A vector that is peripherally delivered must cross the blood-brain barrier (BBB) with an adequate degree of tissue specificity. Rather, DBS surgical techniques may be used to precisely administer the vector to a specific region in the brain. Because nonviral techniques have a briefer duration of achieved gene expression, they are not as suitable for treating neurodegenerative diseases, including PD, despite being technically and conceptually more clear-cut. Using nonviral vectors in experiments usually involves regimens of multiple doses, since there are low transfection rates. This can present problems for translation to human studies if there is a need for repeated intracerebral injections, as there are risks associated<sup>[88]</sup>. A novel study that utilized human glial cell-derived neurotrophic factor (GDNF) gene and a neurotensin polyplex nanoparticle vector in an animal model of PD found that a single intracerebral injection of the non-viral agent may be able to activate a biochemical and functional response, suggesting that this method may still be effective, regardless of the latter concerns<sup>[89]</sup>. Region-specific ligands using intravenous vector administration in alternative studies in animal models of PD using nonviral vectors have helped to maximize tissue specificity<sup>[90]</sup>. Derivation of viral vectors from DNA or RNA are considered a more reasonable approach, as they have the potential ability to create enduring gene expression via episome formation or DNA integration into the host genome<sup>[91]</sup>.

Higher doses of exogenous levodopa are required for PD patients in order to control the progression of symptoms. The enzyme, aromatic amino acid decarboxylase (AADC), is responsible for dopamine production from endogenous or exogenous levodopa. There have been indications that activity of AADC may be diminished in PD. Increasing this enzyme's activity using gene therapy may minimize PD symptoms and lower the amount of L-DOPA needed to maintain them<sup>[91,92]</sup>.

## BEHAVIORAL THERAPY

Even with medical and surgical management, the symptoms of PD may not be completely controlled. While pharmaceutical medications can have positive results, there can also be adverse side effects and limited effectiveness at combating PD symptoms. Furthermore, Parkinson's drugs have little effect on postural instability, balance problems and gait disorders such as freezing of gait (FoG) and stride variability<sup>[93]</sup>. Therefore, physicians must look to alternatives to either replace or supplement medical and surgical treatments while managing PD symptoms. Different types of therapies are available to help patients manage symptoms and the daily struggles that may result from them<sup>[94]</sup>. Physical therapy (PT) and speech therapy (SP) help to manage mobility and motor-related symptoms, with SP focusing on speech abilities<sup>[95]</sup>. Occupational therapy (OT) focuses on enabling patients to participate in the community, work, and home activities<sup>[96]</sup>. These therapies focus on the behavior of the patient and management of symptoms rather than on the supplementation or modification of neural pathways affected by PD.

### Physical therapy

Aside from pharmaceutical treatment, PT is the most adept aid for patients with PD. It is a necessary aspect in the treatment and maintenance of the health of Parkinson's patients. Abnormalities in the cortical silent period (CSP duration) and other corticomotor excitability measures in PD patients have been revealed through single-pulse transcranial magnetic stimulation (TMS) studies. This indicates more outstanding corticomotor excitability in these patients. CSP is primarily mediated by gamma-aminobutyric acid (GABA)-B receptors. GABAergic transmission abnormalities are fundamental elements of the pathophysiology of movement disorders concerning the basal ganglia. Promotion of synaptogenesis and neurogenesis may improve neuronal function through voluntary exercise, which enhances brain-derived neurotrophic factor (BDNF). The level of functional inhibition in an activity-dependent manner is modulated by BDNF. This is accomplished by regulation in the number of GABAergic interneurons. It is suspected that the relationship between the lengthening of CSP and high intensity exercise may have













30. Tayebi N, Stubblefield BK, Park JK, et al. Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease. *Am J Hum Genet* 2003;72:519-34.
31. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. *Mol Genet Metab* 2004;81:70-3.
32. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. *Ann Neurol* 2006;59:459-66.
33. Nutt JG, Burchiel KJ, Comella CL, et al; ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. *Neurology* 2003;60:69-73.
34. Boado RJ, Pardridge WM. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. *Drug Metab Dispos* 2009;37:2299-304.
35. Mohl B, Berman BD, Shelton E, Tanabe J. Levodopa response differs in Parkinson's motor subtypes: A task-based effective connectivity study. *J Comp Neurol* 2017;525:2192-201.
36. Anwar A, Saleem S, Akhtar A, Ashraf S, Ahmed MF. Juvenile Parkinson disease. *Cureus* 2019;11:e5409.
37. Gomez Arevalo G, Jorge R, Garcia S, Scipioni O, Gershanik O. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. *Mov Disord* 1997;12:277-84.
38. Espay AJ, Lang AE. Common myths in the use of levodopa in Parkinson disease: when clinical trials misinform clinical practice. *JAMA Neurol* 2017;74:633-4.
39. Spiegel J, Hellwig D, Samnick S, et al. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. *J Neural Transm (Vienna)* 2007;114:331-5.
40. Pascual A, Hidalgo-Figueroa M, Gómez-Díaz R, López-Barneo J. GDNF and protection of adult central catecholaminergic neurons. *J Mol Endocrinol* 2011;46:R83-92.
41. AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. *Neurotherapeutics* 2014;11:6-23.
42. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. *JAMA* 2014;311:1670-83.
43. Koller WC, Rueda MG. Mechanism of action of dopaminergic agents in Parkinson's disease. *Neurology* 1998;50:S11-4; discussion S44-8.
44. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. *JAMA* 2020;323:548-60.
45. Korczyn AD. Drug treatment of Parkinson's disease. *Dialogues Clin Neurosci* 2004;6:315-22.
46. Ossig C, Reichmann H. Treatment of Parkinson's disease in the advanced stage. *J Neural Transm (Vienna)* 2013;120:523-9.
47. Zibetti M, Merola A, Artusi CA, et al. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. *Eur J Neurol* 2014;21:312-8.
48. Zibetti M, Rizzone M, Merola A, et al. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease. *Acta Neurol Scand* 2013;127:e28-32.
49. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. *Mov Disord* 2009;24:1468-74.
50. Pessoa RR, Moro A, Munhoz RP, Teive HAG, Lees AJ. Apomorphine in the treatment of Parkinson's disease: a review. *Arq Neuropsiquiatr* 2018;76:840-8.
51. Dellapina E, Gerdelat-Mas A, Ory-Magne F, et al. Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. *Mov Disord* 2011;26:153-7.
52. Vanle B, Olcott W, Jimenez J, Bashmi L, Danovitch I, IsHak WW. NMDA antagonists for treating the non-motor symptoms in Parkinson's disease. *Transl Psychiatry* 2018;8:117.
53. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. *Neurology* 1998;50:1323-6.
54. Dashtipour K, Tafreshi AR, Pahwa R, Lyons KE. Extended-release Amantadine for Levodopa-induced Dyskinesia. *Expert Rev Neurother* 2019;19:293-9.
55. Brocks DR. Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective. *J Pharm Pharm Sci* 1999;2:39-46.
56. Zahoor I, Shafi A, Haq E. Pharmacological treatment of Parkinson's disease. In: Stoker TB, Greenland JC, editors. Parkinson's disease: pathogenesis and clinical aspects. Brisbane (AU): Codon Publications; 2018. pp. 129-44.
57. Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson's disease. *Clin Pharmacokinet* 1996;30:463-81.
58. Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. *Neurology* 2010;75:1263-9.
59. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science* 1993;260:1130-2.
60. Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gómez-Díaz R, López-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. *Nat Neurosci* 2008;11:755-61.
61. Arenas E, Trupp M, Åkerud P, Ibáñez CF. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. *Neuron* 1995;15:1465-73.
62. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. *Nat Med* 2003;9:589-95.
63. Vastag B. Biotechnology: Crossing the barrier. *Nature* 2010;466:916-8.

64. Hadaczek P, Wu G, Sharma N, et al. GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model. *Exp Neurol* 2015;263:177-89.
65. Tatarewicz SM, Wei X, Gupta S, Masterman D, Swanson SJ, Moxness MS. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputamenal infusion. *J Clin Immunol* 2007;27:620-7.
66. Chiricozzi E, Lunghi G, Di Biase E, Fazzari M, Sonnino S, Mauri L. GM1 ganglioside is a key factor in maintaining the mammalian neuronal functions avoiding neurodegeneration. *Int J Mol Sci* 2020;21:868.
67. Hawthorne GH, Bernuci MP, Bortolanza M, Tumas V, Issy AC, Del-Bel E. Nanomedicine to overcome current Parkinson's treatment liabilities: a systematic review. *Neurotox Res* 2016;30:715-29.
68. Re F, Gregori M, Masserini M. Nanotechnology for neurodegenerative disorders. *Maturitas* 2012;73:45-51.
69. Kulkarni AD, Vanjari YH, Sancheti KH, Belgamwar VS, Surana SJ, Pardeshi CV. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review. *J Drug Target* 2015;23:775-88.
70. Tsai MJ, Huang YB, Wu PC, et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. *J Pharm Sci* 2011;100:547-57.
71. Walter BL, Vitek JL. Surgical treatment for Parkinson's disease. *Lancet Neurol* 2004;3:719-28.
72. Harris JP, Burrell JC, Struzyna LA, et al. Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease. *NPJ Parkinsons Dis* 2020;6:4.
73. Dostrovsky JO, Hutchison WD, Lozano AM. The globus pallidus, deep brain stimulation, and Parkinson's disease. *Neuroscientist* 2002;8:284-90.
74. Beuter A, Lefaucheur JP, Modolo J. Closed-loop cortical neuromodulation in Parkinson's disease: an alternative to deep brain stimulation? *Clin Neurophysiol* 2014;125:874-85.
75. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. *J Neurosurg* 1992;76:53-61.
76. Obeso JA, Rodríguez MC, Gorospe A, Guridi J, Alvarez L, Macias R. Surgical treatment of Parkinson's disease. *Baillieres Clin Neurol* 1997;6:125-145.
77. Gross RE. What happened to posteroventral pallidotomy for Parkinson's disease and dystonia? *Neurotherapeutics* 2008;5:281-93.
78. Habets JGV, Heijmans M, Kuijf ML, Janssen MLF, Temel Y, Kubben PL. An update on adaptive deep brain stimulation in Parkinson's disease. *Mov Disord* 2018;33:1834-43.
79. Lee DJ, Dallapiazza RF, De Vloot P, Lozano AM. Current surgical treatments for Parkinson's disease and potential therapeutic targets. *Neural Regen Res* 2018;13:1342-5.
80. Follett KA, Weaver FM, Stern M, et al; CSP 468 Study Group. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. *N Engl J Med* 2010;362:2077-91.
81. Stefani A, Lozano AM, Peppe A, et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. *Brain* 2007;130:1596-607.
82. Thevathasan W, Coyne TJ, Hyam JA, et al. Pedunculopontine nucleus stimulation improves gait freezing in Parkinson disease. *Neurosurgery* 2011;69:1248-53; discussion 1254.
83. Kalampokini S, Lyros E, Lochner P, Fassbender K, Unger MM. Effects of subthalamic nucleus deep brain stimulation on facial emotion recognition in Parkinson's disease: a critical literature review. *Behav Neurol* 2020;2020:4329297.
84. Parastarfeizabadi M, Kouzani AZ. Advances in closed-loop deep brain stimulation devices. *J Neuroeng Rehabil* 2017;14:79.
85. Yasuhara T, Kameda M, Sasaki T, Tajiri N, Date I. Cell Therapy for Parkinson's disease. *Cell Transplant* 2017;26:1551-9.
86. Lindvall O, Björklund A. Cell therapy in Parkinson's disease. *NeuroRx* 2004;1:382-93.
87. Axelsen TM, Woldbye DPD. Gene Therapy for Parkinson's disease, an update. *J Parkinsons Dis* 2018;8:195-215.
88. Hitti FL, Yang AI, Gonzalez-Alegre P, Baltuch GH. Human gene therapy approaches for the treatment of Parkinson's disease: an overview of current and completed clinical trials. *Parkinsonism Relat Disord* 2019;66:16-24.
89. Gonzalez-Barrios JA, Lindahl M, Bannon MJ, et al. Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. *Mol Ther* 2006;14:857-65.
90. Huang R, Han L, Li J, et al. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. *J Gene Med* 2009;11:754-63.
91. Denyer R, Douglas MR. Gene therapy for Parkinson's disease. *Parkinsons Dis* 2012;2012:757305.
92. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. *Exp Neurol* 2000;164:2-14.
93. Borriore P, Tranchita E, Sansone P, Parisi A. Effects of physical activity in Parkinson's disease: a new tool for rehabilitation. *World J Methodol* 2014;4:133-43.
94. Radder DLM, Sturkenboom IH, van Nimwegen M, Keus SH, Bloem BR, de Vries NM. Physical therapy and occupational therapy in Parkinson's disease. *Int J Neurosci* 2017;127:930-43.
95. Mahler LA, Ramig LO, Fox C. Evidence-based treatment of voice and speech disorders in Parkinson disease. *Curr Opin Otolaryngol Head Neck Surg* 2015;23:209-15.
96. Dixon L, Duncan D, Johnson P, et al. Occupational therapy for patients with Parkinson's disease. *Cochrane Database Syst Rev* 2007;:CD002813.
97. Fisher BE, Wu AD, Salem GJ, et al. The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson's disease. *Arch Phys Med Rehabil* 2008;89:1221-9.
98. Shu HF, Yang T, Yu SX, et al. Aerobic exercise for Parkinson's disease: a systematic review and meta-analysis of randomized controlled

- trials. *PLoS One* 2014;9:e100503.
99. Tambosco L, Percebois-Macadré L, Rapin A, Nicomette-Bardel J, Boyer FC. Effort training in Parkinson's disease: a systematic review. *Ann Phys Rehabil Med* 2014;57:79-104.
  100. Mehrholz J, Friis R, Kugler J, Twork S, Storch A, Pohl M. Treadmill training for patients with Parkinson's disease. *Cochrane Database Syst Rev* 2010;CD007830.
  101. Herman T, Giladi N, Hausdorff JM. Treadmill training for the treatment of gait disturbances in people with Parkinson's disease: a mini-review. *J Neural Transm (Vienna)* 2009;116:307-18.
  102. Frenkel-Toledo S, Giladi N, Peretz C, Herman T, Gruendlinger L, Hausdorff JM. Treadmill walking as an external pacemaker to improve gait rhythm and stability in Parkinson's disease. *Mov Disord* 2005;20:1109-14.
  103. Maki BE. Gait changes in older adults: predictors of falls or indicators of fear. *J Am Geriatr Soc* 1997;45:313-20.
  104. Arfa-Fatollahkhani P, Safar Cherati A, Habibi SAH, Shahidi GA, Sohrabi A, Zamani B. Effects of treadmill training on the balance, functional capacity and quality of life in Parkinson's disease: a randomized clinical trial. *J Complement Integr Med* 2019;17:/j/jcim.
  105. Herman T, Giladi N, Gruendlinger L, Hausdorff JM. Six weeks of intensive treadmill training improves gait and quality of life in patients with Parkinson's disease: a pilot study. *Arch Phys Med Rehabil* 2007;88:1154-8.
  106. Protas EJ, Mitchell K, Williams A, Qureshy H, Caroline K, Lai EC. Gait and step training to reduce falls in Parkinson's disease. *NeuroRehabilitation* 2005;20:183-90.
  107. Morris ME, Ianssek R, Matyas TA, Summers JJ. Stride length regulation in Parkinson's disease. Normalization strategies and underlying mechanisms. *Brain* 1996;119 ( Pt 2):551-68.
  108. Aguiar LPC, Da Rocha PA, Morris M. Therapeutic dancing for Parkinson's disease. *Int J Gerontol* 2016;10:64-70.
  109. Hackney ME, Earhart GM. Effects of dance on gait and balance in Parkinson's disease: a comparison of partnered and nonpartnered dance movement. *Neurorehabil Neural Repair* 2010;24:384-92.
  110. Cheung C, Bhimani R, Wyman JF, et al. Effects of yoga on oxidative stress, motor function, and non-motor symptoms in Parkinson's disease: a pilot randomized controlled trial. *Pilot Feasibility Stud* 2018;4:162.
  111. Sturkenboom IHWM, Graff MJL, Hendriks JCM, et al. Efficacy of occupational therapy for patients with Parkinson's disease: a randomised controlled trial. *Lancet Neurol* 2014;13:557-66.
  112. Ehgoetz Martens KA, Pieruccini-Faria F, Almeida QJ. Could sensory mechanisms be a core factor that underlies freezing of gait in Parkinson's disease? *PLoS One* 2013;8:e62602.
  113. Ehgoetz Martens KA, Ellard CG, Almeida QJ. Does anxiety cause freezing of gait in Parkinson's disease? *PLoS One* 2014;9:e106561.
  114. Dashtipour K, Tafreshi A, Lee J, Crawley B. Speech disorders in Parkinson's disease: pathophysiology, medical management and surgical approaches. *Neurodegener Dis Manag* 2018;8:337-48.
  115. Fox CM, Ramig LO, Ciucci MR, Sapir S, McFarland DH, Farley BG. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. *Semin Speech Lang* 2006;27:283-99.
  116. Herd CP, Tomlinson CL, Deane KH, et al. Comparison of speech and language therapy techniques for speech problems in Parkinson's disease. *Cochrane Database Syst Rev* 2012;2012:CD002814.
  117. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. *BMC Fam Pract* 2012;13:40.
  118. Videnovic A. Management of sleep disorders in Parkinson's disease and multiple system atrophy. *Mov Disord* 2017;32:659-68.
  119. Morin CM, Bélanger L, LeBlanc M, et al. The natural history of insomnia: a population-based 3-year longitudinal study. *Arch Intern Med* 2009;169:447-53.
  120. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. *CMAJ* 2000;162:225-33.
  121. Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. *Neurology* 2013;80:792-9.
  122. Dobkin RD, Mann SL, Gara MA, Interian A, Rodriguez KM, Menza M. Telephone-based cognitive behavioral therapy for depression in Parkinson disease: a randomized controlled trial. *Neurology* 2020;94:e1764-73.